ABC | Volume 111, Nº3, September 2018

Original Article Marino et al Adiponectin and IVUS-VH Coronary Plaque Characteristics Arq Bras Cardiol. 2018; 111(3):345-353 1. NewbyDE. Triggering of acutemyocardial infarction: beyond the vulnerable plaque. Heart. 2010;96(15):1247-51. 2. Narula J, Garg P, Achenbach S, Motoyama S, Virmani R, Strauss HW. Arithmetic of vulnerable plaques for noninvasive imaging. Nat Clin Pract Cardiovasc Med. 2008;5 Suppl 2:S2-10. 3. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340(2):115-26. 4. Shimada K, Miyazaki T, Daida H. Adiponectin and atherosclerotic disease. Clin Chim Acta. 2004;344(1-2):1-12. 5. Barseghian A, Gawande D, Bajaj M. Adiponectin and vulnerable atherosclerotic plaques. J Am Coll Cardiol. 2011;57(7):761-70. 6. Matsuzawa Y. Adiponectin: Identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler Suppl. 2005;6(2):7-14. 7. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem. 2002;277(29):25863-6. 8. SzmitkoPE,TeohH,StewartDJ,VermaS.Adiponectinandcardiovasculardisease: stateoftheart?AmJPhysiolHeartCircPhysiol.2007;292(4):H1655-63. 9. SattarN,WannametheeG,SarwarN,TchernovaJ,CherryL,WallaceAM,etal. Adiponectinandcoronaryheartdisease:aprospectivestudyandmeta-analysis. Circulation.2006;114(7):623-9.Erratumin:Circulation.2007;115(10):e325. 10. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta. 2007;380(1-2):24-30. 11. deBoerSP,ChengJM,Garcia-GarciaHM,OemrawsinghRM,vanGeunsRJ,Regar E,etal.Relationofgeneticprofileandnovelcirculatingbiomarkerswithcoronary plaquephenotypeasdeterminedbyintravascularultrasound:rationaleanddesign oftheATHEROREMO-IVUSstudy.EuroIntervention.2014;10(8):953-60. 12. Cheng JM, Garcia-Garcia HM, de Boer SP, Kardys I, Heo JH, Akkerhuis KM, et al. In vivo detection of high-risk coronary plaques by radiofrequency intravascular ultrasound and cardiovascular outcome: results of the ATHEROREMO-IVUS study. Eur Heart J. 2014;35(10):639-47. 13. Garcia-GarciaHM, Mintz GS, Lerman A, VinceDG, MargolisMP, van Es GA, etal.Tissuecharacterisationusing intravascularradiofrequencydataanalysis: recommendations for acquisition, analysis, interpretation and reporting. EuroIntervention. 2009;5(2):177-89. 14. Nair A, Margolis MP, Kuban BD, Vince DG. Automated coronary plaque characterisation with intravascular ultrasound backscatter: ex vivo validation. EuroIntervention. 2007;3(1):113-20. 15. García-GarcíaHM, Mintz GS, Lerman A, VinceDG, MargolisMP, van Es GA, etal.Tissuecharacterisationusing intravascularradiofrequencydataanalysis: recommendations for acquisition, analysis, interpretation and reporting. EuroIntervention. 2009;5(2):177-89. 16. Rodriguez-Granillo GA, García-García HM, Mc Fadden EP, Valgimigli M, Aoki J, de Feyter P, et al. In vivo intravascular ultrasound-derived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis. J Am Coll Cardiol. 2005;46(11):2038-42. 17. Erhardt L, Herlitz J, Bossaert L, HalinenM, Keltai M, Koster R, et al; Task force on the management of chest pain .Task force on the management of chest pain. Eur Heart J. 2002;23(15):1153-76. 18. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al; ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST- segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(23):2999-3054. References associated with VH-IVUS derived TCFA lesions, while the association with death was borderline significant. Altogether, a substantial role for adiponectin in plaque vulnerability remains unconfirmed and warrants investigation by other, large studies. Acknowledgements We would like to thank the following interventional cardiologists and technical staff for their contribution to this study: Eric Duckers, MD, PhD; Willem van der Giessen, MD, PhD; Peter P.T. de Jaegere, MD, PhD; Jurgen M.R. Ligthart; Nicolas M.D.A. van Mieghem, MD, PhD; Carl Schultz, MD, PhD; Karen T. Witberg and Felix Zijlstra, MD, PhD. Author contributions Conception and design of the research: Akkerhuis M, Garcia‑Garcia HM, Serruys PW, Boersma E, Kardys I; Acquisition of data: BuljubasicN, Cheng JM, Garcia‑GarciaHM, Regar E, Robert-Jan VG, Serruys PW, Kardys I; Analysis and interpretation of the data: Marino BCA, Buljubasic N, Akkerhuis M, Cheng JM, Garcia-Garcia HM, Regar E, Robert‑Jan VG, Serruys PW, Boersma E, Kardys I; Statistical analysis: Marino BCA; Obtaining financing: Serruys PW, Boersma E, Kardys I; Writing of the manuscript: Marino BCA; Critical revision of the manuscript for intellectual content: Buljubasic N, Akkerhuis M, Cheng JM, Garcia-Garcia HM, Regar E, Robert-Jan VG, Serruys PW, Boersma E, Kardys I. Potential Conflict of Interest No potential conflict of interest relevant to this article was reported. Sources of Funding This study was funded by European Commission, Dutch Government and Netherlands Heart Foundation. Study Association This article is part of the thesis of Doctoral submitted by Barbara C. A. Marino, from Universidade Federal de Minas Gerais. Ethics approval and consent to participate This study was approved by the Ethics Committee of the Erasmus MC under the protocol number NCT01789411. All the procedures in this study were in accordancewith the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study. 351